
WHAT IS CLAIMED IS:

- 1. An antibody that is capable of binding a PF4AR polypeptide.
- 2. The antibody of claim 1 that does not cross-react with a receptor capable of binding another PF4 superfamily member.
- 3. The antibody of claim 1 wherein the PF4AR polypeptide is an IL-8 receptor.
- 4. The antibody of claim 3 wherein the PF4AR polypeptide is an IL-8 type A receptor.
- 5. The antibody of claim 4 that is a monoclonal antibody.
- 6. The antibody of claim 4 that has the isotype IgG1.
- 7. The antibody of claim 1 that neutralizes the activity of a PF4AR polypeptide.
- 8. The antibody of claim 4 that neutralizes the activity of an IL-8 type A receptor.
- 9. The antibody of claim 8 that is a monoclonal antibody designated 2A4, having ATCC Deposit No. 11377.
- 10. The antibody of claim 8 that is a monoclonal antibody designated 9H1, having ATCC Deposit No. 11376.
- 11. A composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.



- 13. A composition comprising the antibody of claim 8 and a pharmaceutically acceptable carrier.
- 14. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 11.
- 15. The method of claim 14 wherein the mammal is a human.
- 16. The method of claim 14 wherein the disorder is an inflammatory bowel disease or a chronic inflammation of the lung.
- 17. The method of claim 14 wherein the composition is administered systemically.
- 18. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 12.
- 19. A method for treating an inflammatory disorder comprising administering to a mammal in need of such treatment an effective amount of the composition of claim 13.

